ClinicalTrials.gg

Stress Disorders, Post-Traumatic clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,688 studies for Stress Disorders, Post-Traumatic across more than 10 countries. 606 are recruiting or about to start. 1,893 of them are mainly about Stress Disorders, Post-Traumatic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 2,862 studies for Stress Disorders, Post-Traumatic. How that becomes 2,687 here

This page counts the studies the registry files under Stress Disorders, Post-Traumatic, and those it files under no condition that list Stress Disorders, Post-Traumaticthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 2,862Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −72List Stress Disorders, Post-Traumatic as a condition, but the registry did not file them under itMost often written as “PTSD - Post Traumatic Stress Disorder” (29), “Post Traumatic Stress Disorder PTSD” (11), and “Post-Traumatic Stress Disorder, PTSD” (8). The registry filed them under other conditions only, most often Combat Disorders (58) and Anxiety Disorders (11).
  3. −110Match it another way29 name it in the title, 5 in a keyword, and 76 by a synonym or other text the search reads.
  4. 2,680Counted here and found by its search21 of them list Stress Disorders, Post-Traumatic in their own words; the registry filed them under no condition.
  5. +7
    Counted here, but its search does not find them
  6. 2,687The count on this page

Status

Completed
1,547
Recruiting
417
Status unknown
199
Not yet recruiting
151
Terminated
132
Withdrawn
103

Phase

Phase 2
323
Phase 3
130
Phase 1
125
Phase 4
105
Early Phase 1
40

Where

United States
1,664
France
144
Canada
126
Israel
103
Germany
52
Sweden
45

Who develops what

Add Stress Disorders, Post-Traumatic to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 4 programs from 4 companies, 3 with this as their studies’ main aim; 3 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 4 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Sep 2027 est.HB-1 · HB BioTech, LLC · Phase 2 main aimNCT07499440 Safety and Efficacy of HB-1 for Post-Traumatic Stress Disorder — primary endpoint: To measure the efficacy of HB-1 on clinician-rated symptoms of Post-Traumatic Stress Disorder in male and female adults (age 18 to 65 years) with Post-Traumatic Stress Disorder. · 200 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Stress Disorders, Post-Traumatic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Psychedelics 23 open · Serotonin receptor agonists 13 open · Stimulants 5 open · Beta blockers 2 open · Antipsychotics 2 open

Coming up

235studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger. 63 (15%) take children under 18. 36 (9%) are for women only and 5 (1%) for men only; 89 (21%) take healthy volunteers.

Recruiting studies that take each age, of 417
AgeWomenMen
1031 (7%)31 (7%)
18362 (87%)331 (79%)
30373 (89%)343 (82%)
40371 (89%)341 (82%)
50362 (87%)340 (82%)
65320 (77%)300 (72%)
75225 (54%)206 (49%)
85200 (48%)181 (43%)

Across all 2,688 studies, recruiting or not: 50% stop at 75 or younger and 40% at 65; 13% take children; 9% are for women only and 3% for men only; 25% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Stress Disorders, Post-Traumatic studies take

Of 118 phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 38 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 133 mo17–54 · 52 studies—42 mo17–59 · 47 studies
Phase 1/223 mo17–35 · 17 studies——
Phase 238 mo23–53 · 118 studies22 mo17–33 · 31 studies46 mo35–59 · 87 studies
Phase 337 mo25–54 · 34 studies——
Phase 450 mo36–71 · 31 studies—52 mo36–77 · 30 studies
Interventional, no phase34 mo17–53 · 1,093 studies—35 mo17–53 · 1,065 studies
Observational34 mo14–53 · 149 studies—34 mo13–54 · 142 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered20

Show 15 more

Studies

Recruiting first, then most recently updated. Showing 50 of 2,688. Browse all 2,688 → or search them.